Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure DOI Creative Commons
Winston Wang,

Danielle B. Green,

Hoang Nhat Pham

и другие.

Biomedicines, Год журнала: 2025, Номер 13(5), С. 1108 - 1108

Опубликована: Май 2, 2025

Cardiac cachexia (CC) is a severe complication of advanced heart failure (HF), characterized by involuntary weight loss and muscle wasting, leading to poor outcomes higher mortality. Despite its severity, CC remains under-recognized undertreated, lacking targeted therapies specifically addressing pathophysiology. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), though beneficial in reducing cardiovascular risk patients with HF, may exacerbate wasting cachectic patients, necessitating further investigation. Non-pharmacological strategies, including tailored nutritional support exercise programs, have shown positive effects on body composition quality life CC. However, there gap recommendations preventive strategies pharmacologic for concomitant GLP-1RA use. This review highlights the multifactorial mechanisms underlying current emerging therapeutic approaches mitigating HF-related sarcopenia while GLP-1RAs.

Язык: Английский

Emerging Therapeutic Strategies in Sarcopenia: An Updated Review on Pathogenesis and Treatment Advances DOI Open Access
Alfred Najm, Adelina-Gabriela Niculescu, Alexandru Mihai Grumezescu

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(8), С. 4300 - 4300

Опубликована: Апрель 12, 2024

Sarcopenia is a prevalent degenerative skeletal muscle condition in the elderly population, posing tremendous burden on diseased individuals and healthcare systems worldwide. Conventionally, sarcopenia currently managed through nutritional interventions, physical therapy, lifestyle modification, with no pharmaceutical agents being approved for specific use this disease. As pathogenesis of still poorly understood there treatment recognized as universally effective, recent research efforts have been directed at better comprehending illness diversifying strategies. In respect, paper overviews new advances correlation its underlying mechanisms. Specifically, review creates an updated framework sarcopenia, describing etiology, pathogenesis, risk factors, conventional treatments, further discussing emerging therapeutic approaches like drug formulations, delivery systems, stem cell therapies, tissue-engineered scaffolds more detail.

Язык: Английский

Процитировано

17

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies DOI

Youle Zheng,

Feng Jin,

Yixin Yu

и другие.

Archives of Pharmacal Research, Год журнала: 2024, Номер 47(4), С. 301 - 324

Опубликована: Апрель 1, 2024

Язык: Английский

Процитировано

14

Near Infrared‐Mediated Intracellular NADH Delivery Strengthens Mitochondrial Function and Stability in Muscle Dysfunction Model DOI Creative Commons

Hui Bang Cho,

Hye‐Ryoung Kim,

Sujeong Lee

и другие.

Advanced Science, Год журнала: 2025, Номер unknown

Опубликована: Янв. 31, 2025

Abstract Mitochondrial transfer emerges as a promising therapy for the restoration of mitochondrial function in damaged cells, mainly due to its limited immunogenicity. However, isolated mitochondria rapidly lose because they produce little energy outside cells. Therefore, this study investigates whether near infrared (NIR)‐mediated nicotinamide adenine dinucleotide (NADH) pre‐treatment enhances and stability mitochondria‐donor cells prior transplantation. Clinical applications NADH, an essential electron donor oxidative phosphorylation process, are restricted cellular uptake NADH. To address this, photo‐mediated method optimizes direct NADH delivery into increases absorption. L6 treated with irradiated NIR enhanced uptake, significantly improving production function. Importantly, improved functional characteristics maintained even after isolation from Primed mitochondria, i.e., those by NIR‐mediated (P‐MT), encapsulated fusogenic liposomes delivered muscle dysfunction. Compared conventional P‐MT promote greater recovery regeneration. These findings suggest that is effective strategy function, has potential lead novel treatments disorders degeneration.

Язык: Английский

Процитировано

0

Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure DOI Creative Commons
Winston Wang,

Danielle B. Green,

Hoang Nhat Pham

и другие.

Biomedicines, Год журнала: 2025, Номер 13(5), С. 1108 - 1108

Опубликована: Май 2, 2025

Cardiac cachexia (CC) is a severe complication of advanced heart failure (HF), characterized by involuntary weight loss and muscle wasting, leading to poor outcomes higher mortality. Despite its severity, CC remains under-recognized undertreated, lacking targeted therapies specifically addressing pathophysiology. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), though beneficial in reducing cardiovascular risk patients with HF, may exacerbate wasting cachectic patients, necessitating further investigation. Non-pharmacological strategies, including tailored nutritional support exercise programs, have shown positive effects on body composition quality life CC. However, there gap recommendations preventive strategies pharmacologic for concomitant GLP-1RA use. This review highlights the multifactorial mechanisms underlying current emerging therapeutic approaches mitigating HF-related sarcopenia while GLP-1RAs.

Язык: Английский

Процитировано

0